228 related articles for article (PubMed ID: 24034490)
21. Neuraminidase inhibitors for preventing and treating influenza in children.
Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
[TBL] [Abstract][Full Text] [Related]
22. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
[TBL] [Abstract][Full Text] [Related]
23. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of neuraminidase inhibitors for severe influenza.
Fry AM
Lancet Respir Med; 2014 May; 2(5):346-8. PubMed ID: 24815800
[No Abstract] [Full Text] [Related]
25. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
Saito R; Sato I; Suzuki Y; Baranovich T; Matsuda R; Ishitani N; Dapat C; Dapat IC; Zaraket H; Oguma T; Suzuki H
Pediatr Infect Dis J; 2010 Oct; 29(10):898-904. PubMed ID: 20442686
[TBL] [Abstract][Full Text] [Related]
26. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.
Dunstan HJ; Mill AC; Stephens S; Yates LM; Thomas SH
BJOG; 2014 Jun; 121(7):901-6. PubMed ID: 24602087
[TBL] [Abstract][Full Text] [Related]
27. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Wolkewitz M; Schumacher M
Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
[No Abstract] [Full Text] [Related]
28. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
[No Abstract] [Full Text] [Related]
29. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Jones M; Del Mar C; Hama R
Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
[No Abstract] [Full Text] [Related]
30. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Antes G; Meerpohl JJ
Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
[No Abstract] [Full Text] [Related]
31. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Takashita E; Fujisaki S; Kishida N; Xu H; Imai M; Tashiro M; Odagiri T;
Influenza Other Respir Viruses; 2013 Nov; 7(6):1390-9. PubMed ID: 23745712
[TBL] [Abstract][Full Text] [Related]
32. Influenza virus resistance to neuraminidase inhibitors.
Samson M; Pizzorno A; Abed Y; Boivin G
Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
[TBL] [Abstract][Full Text] [Related]
33. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
[TBL] [Abstract][Full Text] [Related]
34. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
[TBL] [Abstract][Full Text] [Related]
35. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Abed Y; Schibler M; Checkmahomed L; Carbonneau J; Venable MC; Fage C; Giannotti F; Goncalves AR; Kaiser L; Boivin G
Antivir Ther; 2019; 24(8):581-587. PubMed ID: 32031540
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
[TBL] [Abstract][Full Text] [Related]
38. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
McKimm-Breschkin JL
Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
[TBL] [Abstract][Full Text] [Related]
39. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Hurt AC; Deng YM; Ernest J; Caldwell N; Leang L; Iannello P; Komadina N; Shaw R; Smith D; Dwyer DE; Tramontana AR; Lin RT; Freeman K; Kelso A; Barr IG
Euro Surveill; 2011 Jan; 16(3):. PubMed ID: 21262183
[TBL] [Abstract][Full Text] [Related]
40. Widespread use of neuraminidase inhibitors in Japan.
Sugaya N
J Infect Chemother; 2011 Oct; 17(5):595-601. PubMed ID: 21850418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
